Literature DB >> 15558327

Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).

Daniel T Milton1, Mark G Kris, Jorge E Gomez, Marc B Feinstein.   

Abstract

Bronchorrhea is a condition in which voluminous sputum is produced daily, typically seen with bronchioloalveolar cell carcinoma (BAC). Unless the underlying cancer can be controlled, bronchorrhea causes substantial symptomatic distress. We report two cases of bronchorrhea associated with advanced BAC successfully treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, gefitinib. Prompt resolution of these patients' bronchorrhea, dyspnea, and supplemental oxygen requirements are detailed. Given the limited success of alternative interventions, a trial of gefitinib should be considered for patients with bronchorrhea secondary to BAC.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15558327     DOI： 10.1007/s00520-004-0717-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  12 in total

1.  Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma.

Authors:  S Homma; M Kawabata; K Kishi; E Tsuboi; K Narui; T Nakatani; K Nakata
Journal:  Chest       Date:  1999-05       Impact factor: 9.410

2.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

3.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

4.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

5.  Clinical pattern and pathologic stage but not histologic features predict outcome for bronchioloalveolar carcinoma.

Authors:  Michael I Ebright; Maureen F Zakowski; Jocelyne Martin; Ennapadam S Venkatraman; Vincent A Miller; Manjit S Bains; Robert J Downey; Robert J Korst; Mark G Kris; Valerie W Rusch
Journal:  Ann Thorac Surg       Date:  2002-11       Impact factor: 4.330

6.  Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.

Authors:  Gee-Chen Chang; Tsung-Ying Yang; Nai-San Wang; Chih-Mei Huang; Chi-Der Chiang
Journal:  J Formos Med Assoc       Date:  2003-06       Impact factor: 3.282

7.  A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").

Authors:  Seiji Yano; Takanori Kanematsu; Toyokazu Miki; Yoshinori Aono; Masahiko Azuma; Akihiko Yamamoto; Hisanori Uehara; Saburo Sone
Journal:  Cancer Sci       Date:  2003-05       Impact factor: 6.716

8.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Authors:  Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544

Review 9.  Role of epidermal growth factor receptor activation in regulating mucin synthesis.

Authors:  J A Nadel
Journal:  Respir Res       Date:  2001-02-21

10.  Successful treatment of persistent bronchorrhea by gefitinib in a case with Recurrent Bronchioloalveolar Carcinoma: a case report.

Authors:  Motoshi Takao; Kentarou Inoue; Fumiaki Watanabe; Koji Onoda; Takatsugu Shimono; Hideto Shimpo; Isao Yada
Journal:  World J Surg Oncol       Date:  2003-07-01       Impact factor: 2.754
View more
  1 in total

1.  Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: A case report and literature review.

Authors:  Xian Wen Sun; Yong Jie Ding; Yu Yan Zhang; Pei Li Chen; Ya Ru Yan; Ji Min Shen; Qing Yun Li
Journal:  Mol Clin Oncol       Date:  2018-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.